Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Patent analysis of digital sensors for continuous glucose monitoring

Bibliographic Data

ID22080264
AuthorsOlena Litvinova (0000-0003-1578-7398, National University of Pharmacy, corresponding author), Magdalena Eitenberger (0000-0002-0216-387X, Medical University of Vienna), Aylin Bilir (0000-0003-1432-7269, Medical University of Vienna), Andy Wai Kan Yeung (0000-0003-3672-357X, Medical University of Vienna), Emil D Parvanov (0000-0001-6744-0949, Medical University of Varna), ArunSundar MohanaSundaram (0000-0002-2483-7679, Sathyabama Institute of Science and Technology), Jarosław Olav Horbańczuk (0000-0002-7561-0941, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences), Atanas G Atanasov (0000-0003-2545-0967, Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, corresponding author), Harald Willschke (0000-0002-9093-7563, Medical University of Vienna, corresponding author)
Year2023
Volume11
Pages1205903-1205903
Publication date2023-08-09
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Public Health (JOURNAL)
Journal identifiersISSN: 2296-2565 • E-ISSN: 2296-2565
PublisherFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2023.1205903
PMID37621612
OpenAlexW4385706141
LanguageEN
References cited67

The high need for optimal diabetes management among an ever-increasing number of patients dictates the development and implementation of new digital sensors for continuous glucose monitoring. The purpose of this work is to systematize the global patenting trends of digital sensors for continuous glucose monitoring and analyze their effectiveness in controlling the treatment of diabetes patients of different ages and risk groups. The Lens database was used to build the patent landscape of sensors for continuous glucose monitoring. Retrospective analysis showed that the patenting of sensors for continuous glucose monitoring had positive trend over the analyzed period (2000–2022). Leading development companies are Dexcom Inc., Abbott Diabetes Care Inc., Medtronic Minimed Inc., Roche Diabetes Care Inc., Roche Diagnostics Operations Inc., Roche Diabetes Care Gmbh, and Ascensia Diabetes Care Holdings Ag, among others. Since 2006, a new approach has emerged where digital sensors are used for continuous glucose monitoring, and smartphones act as receivers for the data. Additionally, telemedicine communication is employed to facilitate this process. This opens up new opportunities for assessing the glycemic profile (glycemic curve information, quantitative assessment of the duration and amplitude of glucose fluctuations, and so on), which may contribute to improved diabetes management. A number of digital sensors for minimally invasive glucose monitoring are patented, have received FDA approval, and have been on the market for over 10 years. Their effectiveness in the clinic has been proven, and advantages and disadvantages have been clarified. Digital sensors offer a non-invasive option for monitoring blood glucose levels, providing an alternative to traditional invasive methods. This is particularly useful for patients with diabetes who require frequent monitoring, including before and after meals, during and after exercise, and in other scenarios where glucose levels can fluctuate. However, non-invasive glucose measurements can also benefit patients without diabetes, such as those following a dietary treatment plan, pregnant women, and individuals during fasting periods like Ramadan. The availability of non-invasive monitoring is especially valuable for patients in high-risk groups and across different age ranges. New world trends have been identified in the patenting of digital sensors for non-invasive glucose monitoring in interstitial skin fluid, saliva, sweat, tear fluid, and exhaled air. A number of non-invasive devices have received the CE mark approval, which confirms that the items meet European health, safety, and environmental protection standards (TensorTip Combo-Glucometer, Cnoga Medical Ltd.; SugarBEAT, Nemaura Medical; GlucoTrack, GlucoTrack Inc.), but are not FDA-approved yet. The above-mentioned sensors have characteristics that make them popular in the treatment of diabetes: they do not require implantation, do not cause an organism reaction to a foreign body, and are convenient to use. In the EU, in order to increase clinical safety and the level of transparency about medical devices, manufacturers must obtain certificates in accordance with Regulation (EU) 2017/745, taking into account the transition period. The development of systems, which include digital sensors for continuous glucose monitoring, mobile applications, and web platforms for professional analysis of glycemic control and implementation of unified glycemic assessment principles in mobile healthcare, represent promising approaches for controlling glycaemia in patients

Blood Glucose Self-Monitoring · Continuous glucose monitoring · Continuous monitoring · Diabetes management · Diabetes mellitus · Digital health · Glycemic · Health care · Intensive care medicine · Medical emergency · Operations management · Remote patient monitoring · Telemedicine · Type 2 diabetes · Diabetes and associated disorders · Diabetes Management and Research · Engineering · Medicine · Nursing · Pancreatic function and diabetes · Emergency Medicine

Citation velocityhistorical
Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae